319 related articles for article (PubMed ID: 29757355)
1. A Prospective Study to Monitor for Tuberculosis During Anti-tumour Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease and Immune-mediated Inflammatory Diseases.
Lee CK; Wong SHV; Lui G; Tang W; Tam LS; Ip M; Hung E; Chen M; Wu JC; Ng SC
J Crohns Colitis; 2018 Jul; 12(8):954-962. PubMed ID: 29757355
[TBL] [Abstract][Full Text] [Related]
2. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy.
Ramos GP; Stroh G; Al-Bawardy B; Faubion WA; Papadakis KA; Escalante P
Inflamm Bowel Dis; 2018 Sep; 24(10):2272-2277. PubMed ID: 29718223
[TBL] [Abstract][Full Text] [Related]
4. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease.
Taxonera C; Ponferrada Á; Riestra S; Bermejo F; Saro C; Martín-Arranz MD; Cabriada JL; Barreiro-de Acosta M; de Castro ML; López-Serrano P; Barrio J; Suarez C; Iglesias E; Argüelles-Arias F; Ferrer I; Marín-Jiménez I; Hernández-Camba A; Bastida G; Van Domselaar M; Martínez-Montiel P; Olivares D; Rivero M; Fernandez-Salazar L; Nantes Ó; Merino O; Alba C; Gisbert JP;
J Crohns Colitis; 2018 Nov; 12(11):1270-1279. PubMed ID: 30052856
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
[TBL] [Abstract][Full Text] [Related]
6. Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil.
Amorim RF; Viegas ERC; Carneiro AJV; Esberard BC; Chinem ES; Correa RS; Rodrigues L; Ribeiro-Alves M; Silva KS; de Souza HS; Carvalho ATP
Dig Dis Sci; 2019 Jul; 64(7):1916-1922. PubMed ID: 30673986
[TBL] [Abstract][Full Text] [Related]
7. Chest roentgenography is complementary to interferon-gamma release assay in latent tuberculosis infection screening of rheumatic patients.
Wang PH; Lin CH; Chang TH; Wu CS
BMC Pulm Med; 2020 Aug; 20(1):232. PubMed ID: 32867745
[TBL] [Abstract][Full Text] [Related]
8. Comparison of single and dual latent tuberculosis screening strategies before biologic and targeted therapy in patients with rheumatic diseases: a retrospective cohort study.
Tang I; So H; Luk L; Wong V; Pang S; Lao V; Yip R
Hong Kong Med J; 2020 Apr; 26(2):111-119. PubMed ID: 32245912
[TBL] [Abstract][Full Text] [Related]
9. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
10. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Getahun H; Matteelli A; Abubakar I; Aziz MA; Baddeley A; Barreira D; Den Boon S; Borroto Gutierrez SM; Bruchfeld J; Burhan E; Cavalcante S; Cedillos R; Chaisson R; Chee CB; Chesire L; Corbett E; Dara M; Denholm J; de Vries G; Falzon D; Ford N; Gale-Rowe M; Gilpin C; Girardi E; Go UY; Govindasamy D; D Grant A; Grzemska M; Harris R; Horsburgh CR; Ismayilov A; Jaramillo E; Kik S; Kranzer K; Lienhardt C; LoBue P; Lönnroth K; Marks G; Menzies D; Migliori GB; Mosca D; Mukadi YD; Mwinga A; Nelson L; Nishikiori N; Oordt-Speets A; Rangaka MX; Reis A; Rotz L; Sandgren A; Sañé Schepisi M; Schünemann HJ; Sharma SK; Sotgiu G; Stagg HR; Sterling TR; Tayeb T; Uplekar M; van der Werf MJ; Vandevelde W; van Kessel F; van't Hoog A; Varma JK; Vezhnina N; Voniatis C; Vonk Noordegraaf-Schouten M; Weil D; Weyer K; Wilkinson RJ; Yoshiyama T; Zellweger JP; Raviglione M
Eur Respir J; 2015 Dec; 46(6):1563-76. PubMed ID: 26405286
[TBL] [Abstract][Full Text] [Related]
11. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
12. Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.
Lee EH; Kang YA; Leem AY; Park MS; Kim YS; Kim SK; Chang J; Kim SY
Sci Rep; 2017 Jul; 7(1):6473. PubMed ID: 28743918
[TBL] [Abstract][Full Text] [Related]
13. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
[TBL] [Abstract][Full Text] [Related]
14. A Study of Optimal Screening for Latent Tuberculosis in Patients with Inflammatory Bowel Disease.
Al-Taweel T; Strohl M; Pai M; Martel M; Bessissow T; Bitton A; Seidman E; Afif W
Dig Dis Sci; 2018 Oct; 63(10):2695-2702. PubMed ID: 29968143
[TBL] [Abstract][Full Text] [Related]
15. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy.
Ringrose JS; Sanche SE; Taylor-Gjevre RM
Clin Exp Rheumatol; 2011; 29(5):790-4. PubMed ID: 21961892
[TBL] [Abstract][Full Text] [Related]
16. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
Cui X; Gao L; Cao B
Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201
[TBL] [Abstract][Full Text] [Related]
17. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
18. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.
Kim HC; Jo KW; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Shim TS
Scand J Infect Dis; 2014 Nov; 46(11):763-9. PubMed ID: 25195652
[TBL] [Abstract][Full Text] [Related]
20. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy.
Greveson K; Goodhand J; Capocci S; Woodward S; Murray C; Cropley I; Hamilton M; Lipman M
J Crohns Colitis; 2013 Jun; 7(5):412-8. PubMed ID: 23009739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
